Intranasal Universal Influenza Vaccine: Promising Data on Blocking Virus Transmission

Amy Aspelund shares her insights on intranasal universal influenza vaccines at the World Vaccine Congress Washington 2025.

Cell-Based Therapeutic Vaccination as Adjuvant Therapy for MGMT Unmethylated Glioblastoma

William Decker shares his insights on cell-based therapeutic vaccination as adjuvant therapy for MGMT unmethylated glioblastoma at the World Vaccine Congress Washington 2025.

Clinical Updates for a novel preventative breast cancer vaccine

Olivera Finn shares her insights on clinical updates for a novel preventative breast cancer vaccine at the World Vaccine Congress Washington 2025.

Which vaccination programs with pandemic potential have worked and what else can be done to repurpose COVID facilities and incorporate novel platforms?

Rajinder Suri shares his insights on which vaccination programs with pandemic potential have worked and what else can be done to repurpose COVID facilities and incorporate novel platforms at the World Vaccine Congress Washington 2025.

Benefits and challenges of combining vaccines

Bill Hausdorff shares his insights on the benefits and challenges of combining vaccines at the World Vaccine Congress Washington 2025.

Addressing the burden of long Covid: reaching a global consensus

Miranda Baxa shares her insights on the burden of long Covid at the World Vaccine Congress Washington 2025.   Important documents: ⁠The future of covid⁠  ⁠Addressing the burden of long Covid: reaching a consensus⁠ 

Combining vaccines is the future of vaccination - report from WVCDC 2025

Mark Jit shares his insights on the combination vaccines on the future of vaccination at the World Vaccine Congress Washington 2025.

75th Anniversary of Glucocorticoids - what have we learnt?

Sytske Anne Bergstra at the recent EULAR 2024 chaired a session on the use of glucocorticoids in the therapy of rheumatoid arthritis. What were the key steps in 75 years of glucocorticoid history until they occupied their present therapeutic position?

Update of EULAR recommendations for the treatment of Systemic Sclerosis

Professor Francesco Del Galdo share his thoughts about EULAR Recommendations for the treatment of Systemic Sclerosis.

Promising directions in the treatment of Psoriatic Arthritis

Professor Rik Lories on the current challenges in prevention and treatment of psoriatic arthritis.

Interstitial Lung Disease: from diagnosis to management

Professor Anna-Maria Hoffmann-Vold gave us a review of the most recent data from the diagnosis to the management of interstitial lung disease in RMDs.

What is New : Osteoporosis in Rheumatology

Professor Willem Lems share his thoughts on the latest developments in the diagnosis and therapy of osteoporosis as it pertains to the RMDs.

Effectiveness of Canakinumab for first line steroid free treatment in systemic juvenile idiopathic arthritis - report from EULAR2024

Professor Gerd Horneff explains the results of a  late breaking abstract from EULAR 2024, effectiveness of canakinumab for first line steroid free treatment in systemic onset juvenile idiopathic arthritis/ juvenile Still’s disease.

Early and maintained comparative effectiveness of 5 different classes of advanced therapies in a large multinational cohort of real-world PsA patients

Professor Dennis McGonagle explains the results of an EULAR 2024 late breaking abstract, the PRO-SPIRIT study, early (3-month) and maintained (12-month) comparative effectiveness of 5 different classes of advanced therapies in a large multinational cohort of real-world PsA patients.

Fatigue, Pain and Opioids in Rheumatological Diseases

Professor Rene Westhovens chaired an interesting session during EULAR 2024, where participants learned to recognise the range of pain and fatigue manifestations and impact in Rheumatic and Musculoskeletal Diseases and heared about options for managing different pain mechanisms in RMDs. State of the art and risks of opioid use are discussed and the role of self-management approaches to manage pain and fatigue and reduce opioid use are presented.

Cardiovascular Comorbidities of Rheumatic and Musculoskeletal Diseases

Professor Anja Strangfeld chaired an important session during EULAR 2024 on cardiovascular comorbidities of Rheumatic and Musculoskeletal Diseases and their management.

Medical Devices in Diabetes

Will SGLT2-inhibitors change the landscape?

Innate immunity in pancreatic islet inflammation

The artificial beta cell. When will the dream become reality?

Observational study of insulin pump treatment

The evidence for metformin is unclear?

The ORIGIN Study And Legacy Effects

EMPA-REG OUTCOME - a long-term, outcom study of empagliflozin in pateints with T2D at high CV risk

Principal investigator presenting the results of EMPA-REG OUTCOME trial

Mathematic modelling of fibrinolysis

Pre and perioperative factors modulate fibrinolysis in arthroplasty patients

Cellular and mechanical modulators of fibrin structure

Platelets, NETs and Immunity

Mechanisms by which DNA, histones and NETs stabilise clots

Free fatty acids modulate thrombin activity ov fibrinogen and destabilise fibrin clots

Genetics of thrombosis